


9. Acute Asthma Exacerbation Algorithm

This clinical pathway is intended to supplement, rather than substitute for, professional judgment and may be changed depending upon a patient's individual needs. Failure to comply with this pathway does not represent a breach of the standard of care.



| Medication | Dose | Comments |
|---|---|--|
| Inhaled SABA | | |
| Salbutamol | | |
| Nebulizer solution (0.63 mg/3 mL, 1.25mg/3mL, 2.5 mg/3 mL, 5.0 mg/mL) | 5 mg every 20 min for 3 doses, then 2.5–10 mg every 1–4 h as needed, or 10–15 mg/h continuously | Only selective β -agonists are recommended. For optimal delivery, dilute aerosols to minimum of 3 mL at gas flow of 6–8 L/min. Use large-volume nebulizers for continuous administration. May mix with ipratropium nebulizer solution. |
| MDI (90 μ g/puff) | 4–8 puffs every 20 min up to 4h, then every 1–4 h as needed | In mild to moderate exacerbations, MDI plus valved holding chamber is as effective as nebulized therapy with appropriate administration technique and coaching by trained personnel. |
| Systemic (Injected) β2-Agonists | | |
| * Adrenaline 1:1,000 (1 mg/mL) | 0.3–0.5 mg every 20 min for 3 doses SC | No proven advantage of systemic therapy over aerosol |
| Anticholinergics | | |
| Ipratropium bromide | | |
| Nebulizer solution (0.25mg/mL) | 0.5 mg every 20 min for 3 doses, then as needed | May mix in same nebulizer with salbutamol. Should not be used as first-line therapy; should be added to SABA therapy for severe exacerbations. The addition of Ipratropium has not been shown to provide further benefit once the patient is hospitalized. |
| MDI (18 μ g/puff) | 8 puffs every 20 min as needed up to 3 h | Should use with valved holding chamber. Studies have examined Ipratropium bromide MDI for up to 3 h. |
| Ipratropium with salbutamol | | |
| Nebulizer solution (Each 3-mL vial contains 0.5mg ipratropium bromide and 2.5 mg salbutamol.) | 3 mL every 20 min for 3 doses, then as needed | May be used for up to 3 h in the initial management of severe exacerbations. The addition of ipratropium to salbutamol has not been shown to provide further benefit once the patient is hospitalized. |
| MDI (Each puff contains 18 μ g Ipratropium bromide and 90 μ g salbutamol.) | 8 puffs every 20 min as needed up to 3 h | Should use with valved holding chamber. |
| Systemic Corticosteroids | | |
| Prednisone | 40–80 mg/d in 1 or 2 divided doses until PEF reaches 70% of predicted or personal best | For outpatient “burst,” use 40–60 mg in single or 2 divided doses for a total of 5–10 d. |
| Hydrocortisone | 200mg IV then 1mg/kg/dose IV QID | Only if patient cannot tolerate PO corticosteroids |
| ED = emergency department; ICS = inhaled corticosteroid; MDI = metered-dose inhaler; PEF = peak expiratory flow; SABA = short-acting β2-adrenergic agonist Notes: There is no known advantage for higher doses of corticosteroids in severe asthma exacerbations, nor is there any advantage for intravenous administration over oral therapy provided gastrointestinal transit time or absorption is not impaired. The total course of systemic corticosteroids for an asthma exacerbation requiring an ED visit or hospitalization may last from 3 to 10 days. For corticosteroid courses of <1 week, there is no need to taper the dose. For slightly longer courses (e.g., up to 10 d), there probably is no need to taper, especially if patients are concurrently taking ICSs. ICSs can be started at any point in the treatment of an asthma exacerbation. | | |